Call (415) 636-9700 Phone Mon–Fri 8a–8p · Sat 9a–5p

Staying Power: How Long People Take Spravato

Ketamine therapy

Staying Power: How Long People Take Spravato

Nearly everyone who starts Spravato asks how long they will be on it. The research gives a rough answer, in three stretches.

The first stretch is usually 4 to 12 weeks. That range comes from a 2026 panel of 30 European psychiatrists (Young et al., 2026). After it, the panel suggested continuing for about 6 to 9 months.

Many people stay longer. One study followed 183 people for up to 136 weeks, a little over two and a half years (Reif et al., 2026)*. Of those whose depression had mostly lifted (remission), 79% had not relapsed or stopped treatment.

Everyone in that study took Spravato, so there was no placebo group to compare against.

Timeline of Spravato treatment: first phase 4 to 12 weeks, continued treatment about 6 to 9 months, long-term care 12 months or longer

People who kept taking Spravato after they improved had about half the risk of relapse (Xie et al., 2026). A 2026 review of 43 studies by a Toronto team found the same thing: relapse was common after people stopped (Vasudeva et al., 2026).

Stopping a drug can also cause withdrawal symptoms, and those symptoms can make relapse look more common than it is (Moncrieff et al., 2021).

How long you stay depends on your history, your other medicines and how you respond. A licensed clinician can work through that with you.

Exxceed Wellness offers evaluations in Hayward and by telehealth across California. If you are thinking about harming yourself, call or text 988 right away.

Keep reading

Educational information only, not medical advice. If you are in crisis, call or text 988.

Sources

  1. Young, A. H., et al. (2026). European Neuropsychopharmacology, 113, 112907. https://doi.org/10.1016/j.euroneuro.2026.112907
  2. Reif, A., et al. (2026). ESCAPE-LTE. European Neuropsychopharmacology, 107, 112801. https://doi.org/10.1016/j.euroneuro.2026.112801
  3. Xie, J., Pu, C., & Sun, M. (2026). Intranasal esketamine plus oral antidepressant for treatment-resistant depression: acute induction and maintenance relapse-prevention outcomes in a systematic review and meta-analysis. Frontiers in Psychiatry, 17, 1774549. https://doi.org/10.3389/fpsyt.2026.1774549
  4. Vasudeva, S., et al. (2026). Psychiatry Research, 367, 117556. https://doi.org/10.1016/j.psychres.2026.117556
  5. Moncrieff, J., Jakobsen, J. C., & Bachmann, M. (2021). BMJ Evidence-Based Medicine, 27(4), 246-250. https://doi.org/10.1136/bmjebm-2021-111743

*Five of the 14 authors of the ESCAPE-LTE study are employed by Johnson & Johnson, the manufacturer of Spravato. Most of the large Spravato trials were run or funded by the manufacturer.

Leave A Comment

Your email address will not be published. Required fields are marked *

Serving the East Bay: Hayward, CA  ·  Castro Valley, CA  ·  San Lorenzo, CA  ·  San Leandro, CA  ·  Union City, CA  ·  Newark, CA  ·  Fremont, CA